Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
| Autor: | Stephan Wagner, Thomas Demant, Michaela Schmitz, Andrea Bedynek, Stefan Bilz, Ulrich Keller |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Very low-density lipoprotein medicine.medical_specialty multicompartmental model Apolipoprotein B Atorvastatin stable isotopes Hyperlipidemias QD415-436 Biochemistry chemistry.chemical_compound Endocrinology Fenofibrate Leucine Internal medicine medicine Humans Pyrroles Apolipoproteins B Triglyceride biology Apolipoprotein A-I Cholesterol Catabolism Anticholesteremic Agents nutritional and metabolic diseases Cell Biology Metabolism Middle Aged apolipoprotein metabolism Lipids Kinetics chemistry Heptanoic Acids Apolipoprotein B-100 biology.protein lipids (amino acids peptides and proteins) medicine.drug |
| Zdroj: | Journal of Lipid Research, Vol 45, Iss 1, Pp 174-185 (2004) |
| DOI: | 10.5451/unibas-ep38660 |
| Popis: | Kinetics of apo B and apo AI were assessed in 8 patients with mixed hyperlipidemia at baseline and after 8 weeks of atorvastatin 80 mg q.d. and micronised fenofibrate 200 mg q.d. in a cross-over study. Both increased hepatic production and decreased catabolism of VLDL accounted for elevated cholesterol and triglyceride concentrations at baseline. Atorvastatin significantly decreased triglyceride, total, VLDL and LDL cholesterol and apo B concentrations (-65%, -36%, -57%, -40% and -33%, respectively, Ptextless0.05). Kinetic analysis revealed that atorvastatin stimulated the catabolism of apo B containing lipoproteins, enhanced the delipidation of VLDL1 and decreased VLDL1 production. Fenofibrate lowered triglycerides and VLDL cholesterol (-57% and -64%, respectively, Ptextless0.05) due to enhanced delipidation of VLDL1 and VLDL2 and increased VLDL1 catabolism. Changes of HDL particle composition accounted for the increase of HDL cholesterol during atorvastatin and fenofibrate (18% and 23%, Ptextless0.01). Only fenofibrate increased apo AI concentrations through enhanced apo AI synthesis (45%, Ptextless0.05). We conclude that atorvastatin exerts additional beneficial effects on the metabolism of apo B containing lipoproteins unrelated to an increase in LDL receptor activity. Fenofibrate but not atorvastatin increases apo AI production and plasma turnover. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|